Previous 10 | Next 10 |
2023-12-13 16:59:17 ET Gainers: Codexis ( CDXS ) +16% . Nubia Brand International ( NUBI ) +13% . E.W. Scripps Company ( SSP ) +5% . WAVE Life Sciences ( WVE ) +5% . Losers: Amtech Systems ( ASYS ) -31% . Mont...
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conferenc...
2023-11-09 13:37:50 ET More on Monte Rosa Therapeutics Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value Monte Rosa Therapeutics prices offering to raise $25M Roche in pact with Monte Rosa to develop cancer and neuro drugs Seeking Alpha&...
Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel molecular glue degraders targeting cancer and neu...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Monte Rosa Therapeutics Inc. (GLUE) is expected to report $-0.75 for Q3 2023
Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid arthritis Investigational New Drug filing for MRT-6160 expected in 1H 2024 D...
2023-10-31 08:56:11 ET Summary Monte Rosa Therapeutics is making progress in developing molecular glue degraders to target undruggable diseases. The company has released preliminary PK/PD data for its MGD MRT-2359, showing promising results in MYC-driven solid tumors. Monte Ro...
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncolo...
2023-10-26 17:46:55 ET More on Monte Rosa Therapeutics Roche in pact with Monte Rosa to develop cancer and neuro drugs Seeking Alpha’s Quant Rating on Monte Rosa Therapeutics Historical earnings data for Monte Rosa Therapeutics Financial information fo...
News, Short Squeeze, Breakout and More Instantly...
Monte Rosa Therapeutics Inc. Company Name:
GLUE Stock Symbol:
NASDAQ Market:
Monte Rosa Therapeutics Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside cha...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 202...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected ...